The Top Ten 483’s of 2023
Find out everything you need to know about the FDA's Top 483 trends and observations going into 2024.
Get an insider’s view of the latest FDA 483 observations.
FDA inspections are required when operating a life sciences company. We will help you detect vulnerabilities in your organization that the FDA is likely to identify during their next visit!
In this webinar, we will:
- Provide the Top 10 most cited 483 findings for medical devices and pharmaceuticals.
- Discuss the FDA’s ever-evolving focus over the last ten years.
- Discuss how you can prepare for your next inspection.
- Answer your questions live during our expert Q&A session.
Meet The Speakers
Dean Gionis
Director of Business Development
Dean Gionis is a client-centric business development professional with over 20 years of experience leading business development and sales operations within various organizations.
As Director of Business Development for Compliance Team, Dean has implemented initiatives to enhance our customer experience and account relationships.
Regina Fullin
Vice President of RA/QA Consulting
Regina’s regulatory compliance consulting and project management experience includes advising and assisting clients with developing and implementing robust quality systems.
Through consulting and project management, the goals is to achieve ever-increasing regulatory compliance, process control and product quality.
© Compliance Team LLC. All rights reserved.